Jump to content

LG-120907

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 00:07, 25 July 2022 (Add: s2cid. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | Category:Genito-urinary system drug stubs | #UCB_Category 375/592). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

LG-120907
Clinical data
Other names1,2,3,4-Tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinoline
Drug classNonsteroidal antiandrogen
Identifiers
  • 2,2-Dimethyl-6-(trifluoromethyl)-1,9-dihydropyrido[3,2-g]quinolin-8-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC15H13F3N2O
Molar mass294.277 g·mol−1
3D model (JSmol)
  • CC1(C=CC2=C(N1)C=C3C(=C2)C(=CC(=O)N3)C(F)(F)F)C
  • InChI=1S/C15H13F3N2O/c1-14(2)4-3-8-5-9-10(15(16,17)18)6-13(21)19-12(9)7-11(8)20-14/h3-7,20H,1-2H3,(H,19,21)
  • Key:MMLSXRYBGYGQEP-UHFFFAOYSA-N

LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group which was developed by Ligand Pharmaceuticals along with selective androgen receptor modulators (SARMs) like LG-121071 and was never marketed.[1][2] [3][4] The drug is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM and has been found to inhibit growth of the ventral prostate and seminal vesicles in male rats without increasing circulating levels of luteinizing hormone or testosterone.[1][2][3] However, this tissue selectivity has not been assessed in humans.[5] LG-120907 is orally active and shows greater oral potency than the arylpropionamide NSAA flutamide.[1][3][4]

The 7-fluoro derivative of LG-120907, LG-105, is also a potent NSAA, and appears to possess greater potency in comparison.[3] Conversely, the 6-ethyl, 8-didesmethyl analogue of LG-120907, LG-121071, is a SARM with potent androgenic activity equivalent to that of dihydrotestosterone (DHT).[1][3]

References

  1. ^ a b c d Chengalvala, Murty; Oh, Thomas; Roy, Arun K (2005). "Selective androgen receptor modulators". Expert Opinion on Therapeutic Patents. 13 (1): 59–66. doi:10.1517/13543776.13.1.59. ISSN 1354-3776. S2CID 219188263.
  2. ^ a b Mohler, Michael L; Nair, Vipin A; Hwang, Dong Jin; Rakov, Igor M; Patil, Renukadevi; Miller, Duane D (2005). "Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates". Expert Opinion on Therapeutic Patents. 15 (11): 1565–1585. doi:10.1517/13543776.15.11.1565. ISSN 1354-3776. S2CID 96279138.
  3. ^ a b c d e Gao W, Kim J, Dalton JT (2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharm. Res. 23 (8): 1641–58. doi:10.1007/s11095-006-9024-3. PMC 2072875. PMID 16841196.
  4. ^ a b Nyrönen TH, Söderholm AA (2010). "Structural basis for computational screening of non-steroidal androgen receptor ligands". Expert Opin Drug Discov. 5 (1): 5–20. doi:10.1517/17460440903468680. PMID 22823968. S2CID 21630468.
  5. ^ Rob Bradbury (30 January 2007). Cancer. Springer Science & Business Media. pp. 67–. ISBN 978-3-540-33120-9.



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=LG-120907&oldid=1100254044"